COMP <GO>
CORT vs PTGX // ENTERPRISE SCALE & MARKET CAP
Corcept Therapeutics Incorporated (NASDAQ) VS. Protagonist Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CORT 6
— PTGX 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: PTGX
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
market-cap
$8.77B
LAST: $139.37 (-3.78%) • MKT CAP: $9.37B
market-cap
$9.37B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. PTGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | PTGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | -16.70% | +21.50 | CORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 0.60% | +0.93 | CORT | /fcf-yield <GO> |
| Operating Margin | 5.90% | -6.00% | +11.90 | CORT | /operating-margins <GO> |
| Net Profit Margin | 13.10% | -5.00% | +18.10 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 0.00% | +12.80 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.6 | 57.7 | -30.10 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.99 | -0.11 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 31.0x | +47.30 | PTGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $8.77B | $9.37B | -$604.1M | PTGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | PTGX REV | CORT GROSS % | PTGX GROSS % | CORT FCF | PTGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $442.8M | 98.3% | — | $141.8M | $56.1M |
| FY 2024 | $675.0M | $708.0M | 98.4% | — | $196.1M | $182.8M |
| FY 2023 | $482.4M | $262.2M | — | — | $105.0M | -$70.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
PTGX // BETA 0.99